Kodiak Sciences (KOD) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.24B and a free-cash-flow yield of -2.6%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 2.2/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Leading · +438.9% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-22.2%
How far the last close sits under the highest price of the past five years.
Market cap
$6.24B
Trailing P/E
—
Price / book
102.4
Price / sales
—
FCF yield
-2.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
2.0
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
KOD earnings
Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$1.01).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 13, 2026
-$1.05
-$0.96
-9.4%
$0
Q1 2026
May 7, 2026
-$0.94
-$1.01
+6.9%
$0
Q4 2025
Mar 31, 2026
-$1.04
-$1.05
+0.9%
$0
Q3 2025
Nov 13, 2025
-$1.16
-$1.04
-11.5%
$0
KOD analyst price target
Median target $122.00 from 6 analysts, ranging $103.00 – $145.00.
Nama's AI scorecard currently rates Kodiak Sciences Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does KOD report earnings?
Kodiak Sciences's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$1.01.
What is the KOD price target?
The median analyst price target from 6 analysts is $122.00, with a range of $103.00 – $145.00.
Is KOD Shariah compliant?
Nama's AAOIFI-style screen reads Kodiak Sciences as Can't Tell. A figure the screen needs is missing, so it can't tell.